Program
glecirasib
Also written as “JAB-21822”, “JAB-21822 (KRAS G12C inhibitor)” and “Glecirasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Appendiceal Neoplasms · Pancreatic Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allist Pharmaceuticals | 96 open or running | phase 3since May 9, 2024 | Jul 26, 2021 | Dec 31, 2026phase 2 · NCT06008288 |
| Abbisko Cayman | 11 open or running | phase 2since Sep 2, 2025 | Sep 2, 2025 | Dec 30, 2028phase 2 · NCT07164170 |
| Jacobio Pharmaceuticals | 10 open or running | phase 2since Jul 26, 2021 | Jul 26, 2021 | none ahead |
| Sichuan Biokin Pharmaceutical | 11 open or running | phase 2since Sep 14, 2026 | Sep 14, 2026 | Dec 2028phase 2 · NCT07827261 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Allist PharmaceuticalsAllist Pharmaceuticals · NCT05009329 · 315 enrolled · China
- Jul 26, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Jacobio PharmaceuticalsJacobio Pharmaceuticals · NCT05002270 · 29 enrolled · United States
- Dec 27, 2021Phase 2 study in Appendiceal NeoplasmsAllist Pharmaceuticals · NCT05194995 · 48 enrolled · China
- Mar 3, 20222 phase 2 studies in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05276726, NCT05288205
- Apr 23, 2023Phase 1 study in Food Effect in Healthy ParticipantsAllist Pharmaceuticals · NCT05875493 · 18 enrolled · China
- Jun 6, 2023Phase 1 study in Mass Balance Study in Healthy SubjectsAllist Pharmaceuticals · NCT05920941 · 6 enrolled · China
- Aug 18, 2023Phase 2 study in Pancreatic NeoplasmsAllist Pharmaceuticals · NCT06008288 · 88 planned · China
- Nov 29, 2023Phase 1 study in Healthy SubjectsAllist Pharmaceuticals · NCT06162169 · 66 enrolled · China
- May 9, 2024Phase 3 study in Advanced Non-squamous Non-small-cell Lung CancerAllist Pharmaceuticals · NCT06416410 · 392 planned · China
- Sep 2, 2025Abbisko Cayman's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Abbisko CaymanAbbisko Cayman · NCT07164170 · 86 planned · China
- Sep 14, 2026Sichuan Biokin Pharmaceutical's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07827261 · 36 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Pancreatic NeoplasmsAllist Pharmaceuticals · NCT06008288
- Mar 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05288205
- Aug 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05276726
- Dec 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungSichuan Biokin Pharmaceutical · NCT07827261
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07827261Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 36 |
| NCT07164170Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Abbisko Cayman | Dec 30, 2028 | 86 |
| NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer · China | 3 | Recruiting | Allist Pharmaceuticals | Sep 30, 2029 | 392 |
| NCT06162169Healthy Subjects · China | 1 | Completed | Allist Pharmaceuticals | Feb 20, 2024 | 66 |
| NCT06008288Pancreatic Neoplasms · China | 2 | Recruiting | Allist Pharmaceuticals | Dec 31, 2026 | 88 |
| NCT05920941Mass Balance Study in Healthy Subjects · China | 1 | Completed | Allist Pharmaceuticals | Aug 9, 2023 | 6 |
| NCT05875493Food Effect in Healthy Participants · China | 1 | Completed | Allist Pharmaceuticals | Jun 14, 2023 | 18 |
| NCT05288205Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Allist Pharmaceuticals | Mar 2027 | 240 |
| NCT05276726Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Allist Pharmaceuticals | Aug 2027 | 104 |
| NCT05194995Appendiceal Neoplasms · China | 2 | Active, not recruiting | Allist Pharmaceuticals | Apr 30, 2025 | 48 |
| NCT05009329Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Allist Pharmaceuticals | Aug 2026 | 315 |
| NCT05002270Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Jacobio Pharmaceuticals | Feb 12, 2025 | 29 |
How it is read
Names in the registry
- “JAB-21822”, 10 entries
- “JAB-21822 (KRAS G12C inhibitor)”, 3 entries
- “Glecirasib”, 1 entry
- “JAB 21822”, 1 entry
- “ABSK043 in combination with Glecirasib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Appendiceal Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.